Aytu BioScience Inc. acquired the rights to urinary tract infection drug Primsol, broadening the Englewood-based firm's portfolio of urology products, officials announced Tuesday.
By Alicia WallaceThe Denver Post, Denver Post: Business
Tue, 10/06/2015 - 7:11am
Aytu BioScience Inc. acquired the rights to urinary tract infection drug Primsol, broadening the Englewood-based firm's portfolio of urology products, officials announced Tuesday.